StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$146.58+2.23 (+1.54%)

Close on Nov 18, 2026Market cap $2.11BP/E –Yield –

Palvella Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Palvella Therapeutics's pe ratio was 0.7× on Jan 31, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jan 31, 20250.7×+0.1
2024Dec 31, 20240.6×–

More Palvella Therapeutics figures

See a number that looks wrong?